Royalty Pharma PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 15 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 48.88.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Royalty Pharma PLC is 8.38, ranking 71 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 609.29M, representing a year-over-year increase of 7.90%, while its net profit experienced a year-over-year increase of 47.02%.
Key Metrics
The current valuation score of Royalty Pharma PLC is 7.60, ranking 58 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 25.35, which is 1489.24% below the recent high of 402.86 and 62.52% above the recent low of 9.50.
The current earnings forecast score of Royalty Pharma PLC is 8.75, ranking 10 out of 159 in the Pharmaceuticals industry. The average price target is 45.00, with a high of 56.00 and a low of 34.67.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Royalty Pharma PLC is 9.38, ranking 27 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 46.76 and the support level at 40.70, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Royalty Pharma PLC is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 82.63%, representing a quarter-over-quarter decrease of 1.24%. The largest institutional shareholder is Baillie Gifford, holding a total of 17.01M shares, representing 3.98% of shares outstanding, with 25.17% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Royalty Pharma PLC is 9.15, ranking 16 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Royalty Pharma PLC’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
